SCHEMBL1038893

SCHEMBL1038893

Cc1ccc(S(=O)(=O)Cl)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.44
CCR5 P51681 1/20 0.44
CCR8 P51685 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SLC40A1 Q9NP59 1/20 0.42
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
HSP90AA1 P07900 1/20 0.41
CXCR5 P32302 1/20 0.41
APLNR P35414 1/20 0.41
CCR6 P51684 1/20 0.41
GFER P55789 1/20 0.41
MAPT P10636 3/20 0.38
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.38
CA12 O43570 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5695563 0.98 CCR1 (0.43) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL486163 0.80 CCR1 (0.46) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL29733038 0.78 CCR1 (0.50) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL2633881 0.78 CCR1 (0.50) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL51542 0.78 CA1 (0.61) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL20256091 0.78 SLC40A1 (0.49) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL12659996 0.77 KDM4E (0.44) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL22792202 0.77 CCR1 (0.43) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL27769847 0.77 RAB9A (0.44) CCR1CCR5CCR8HDAC6SLC40A1
SCHEMBL31527849 0.77 CA12 (0.59) CCR1CCR5CCR8HDAC6SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0897914-B1 Process for the preparation of 2,5-disubstitued pyridines HOFFMANN LA ROCHE (CH) 2004-05-26 EP claimed
US-6080866-A A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 2000-06-27 US claimed
CN-1210105-A Process for preparation of 2,5-disubstituted pyridines HOFFMANN LA ROCHE (CH) 1999-03-10 CN claimed
EP-0897914-A1 Process for the preparation of 2,5-disubstitued pyridines F. HOFFMANN-LA ROCHE AG (CH) 1999-02-24 EP claimed
WO-2026104681-A1 NEW SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 WO disclosed
US-20240368123-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-11-07 US disclosed
EP-4393920-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-07-03 EP disclosed
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed
CN-117836294-A Biological antagonist containing aromatic ring, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-04-05 CN disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 CN disclosed
WO-2023025277-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-03-02 WO disclosed
US-20030232848-A1 Pyrazole compositions PFIZER INC. 2003-12-18 US disclosed
US-6573270-B1 Endothelin receptor antagonists PFIZER INC. 2003-06-03 US disclosed
CN-1103335-C Process for preparation of 2,5-disubstituted pyridines HOFFMANN LA ROCHE (CH) 2003-03-19 CN disclosed
EP-1072597-A1 Pyrazoles and their use as endothelin antagonists Pfizer Limited (GB) 2001-01-31 EP disclosed
US-6080866-A A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 2000-06-27 US disclosed
CN-1210105-A Process for preparation of 2,5-disubstituted pyridines HOFFMANN LA ROCHE (CH) 1999-03-10 CN disclosed
EP-0897914-A1 Process for the preparation of 2,5-disubstitued pyridines F. HOFFMANN-LA ROCHE AG (CH) 1999-02-24 EP disclosed
US-5837708-A CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS HOFFMANN-LA ROCHE INC. (US) 1998-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232848-A1 Pyrazole compositions EDNRB, EDNRA, AGTR1 CCR1 236/4885CCR5 898/4885CCR8 2383/4885
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 CCR1 1715/4885CCR5 3403/4885CCR8 1800/4885
US-20240368123-A1 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF REN, BDKRB2, BDKRB1 CCR1 1558/4885CCR5 1155/4885CCR8 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.